Travere Therapeutics stock hit an important technical milestone, with its Relative Strength (RS) Rating moving into the 90-plus percentile with an improvement to 95.
As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength. IBD's unique rating tracks price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
History shows that the best stocks often have an RS Rating north of 80 at the beginning of a new climb.
See How IBD Helps You Make More Money In Stocks
Is Travere Therapeutics Stock A Buy?
Travere Therapeutics stock has been trading in a first stage consolidation. It's trading at the 50-day line, but it's not currently offering a proper buying opportunity. See if the stock goes on to form a chart pattern that could launch a new move. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips. Also, check out "Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks."
EPS growth declined in the company's most recent report from 0% to -18%, but the top line rose from 13% to 33%. Travere Therapeutics will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022 after the close.
The San Diego, Calif.-based company holds the No. 50 rank among its peers in the Medical-Biomed/Biotech industry group. Vertex Pharmaceuticals, Amphastar Pharmaceutcls and Regeneron Pharmaceutical are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharma Industry And Stock News."
